Boston Scientific Corporation (BSX) 2026 Q3 法說會逐字稿

內容摘要

  1. 摘要
    • Q3 2026 營收年增 1.5%,低於原先 3%-5% 指引;調整後 EPS $0.73,年減 3%,低於 $0.80-$0.82 指引,主因為網路攻擊事件影響
    • 下修 Q4 2026 指引:預期營收年減 1%-3%,調整後 EPS $0.77-$0.79;全年營收成長約 4%,EPS $3.16-$3.18,並預期 2027 年營收與 EPS 難以成長
    • 市場反應:管理層強調已啟動重組與成本控管,並預期 2028 年恢復成長動能,2029 年進一步加速
  2. 成長動能 & 風險
    • 成長動能:
      • Interventional Cardiology、Vascular、IO&E 及 Neuromodulation 事業群持續表現強勁
      • 多項新產品與創新平台(如 AGENT DCB、SEISMIQ IVL、Ranger 035、Nalu PNS、Cartesia X lead 等)推動未來成長
      • Penumbra 併購案預計 2027 年初完成,將強化心血管產品線與長期成長潛力
      • 重組計畫預計三年內帶來超過 5 億美元成本節省,提升營運效率
    • 風險:
      • WATCHMAN 與 EP 兩大業務受競爭與市場動態影響,2027 年仍將持續壓抑整體成長
      • 中國市場價格壓力加劇,2027 年將對營收與毛利率造成進一步負面影響
      • 網路攻擊事件造成短期營運與財務衝擊,且 Q4 仍有庫存調整壓力
      • 部分新產品時程延後,影響短期成長動能
  3. 核心 KPI / 事業群
    • 美國營收持平,歐洲中東非洲營收年增 6%,亞太年減 1%
    • Neuromodulation 銷售年增 13%,Pain 產品線表現亮眼
    • Urology 銷售年減 3%,受中國價格壓力與網路攻擊影響
    • Endoscopy 銷售年減 1%,中國 VBP 與網路攻擊為主因
    • Interventional Cardiology 年增 19%,Vascular Therapies 年增 1%,IO&E 年增 5%
    • Cardiac Rhythm Management 年減 2%,Diagnostics 年增高個位數,低壓與高壓分別年減中個位數與低個位數
    • WATCHMAN 銷售年減 6%(美國年減 7%,國際年增 4%);美國單獨手術年減高雙位數,合併手術年增約 35%
    • EP 銷售年減 5%(美國年減 8%,國際年增 2%)
  4. 財務預測
    • 2026 全年營收成長約 4.25%,有機成長約 3.75%
    • 2026 全年調整後毛利率預期低於 2025 年,主因產品組合、供應鏈投資與網路攻擊影響
    • 2026 全年調整後營業利潤率約 27.6%
    • 2026 全年自由現金流預估約 36 億美元,資本支出約 1.8 億美元(Q3 數據)
  5. 法人 Q&A
    • Q: Q3 網路攻擊實際影響為何?為何 Q4 仍有影響?2027 年無成長展望是保守還是有新資訊?
      A: Q3 網路攻擊造成約 300 bps 營收衝擊(約 1.5 億美元),EPS 減少 $0.07。Q4 仍有 200-300 bps 影響,因客戶庫存調整。2027 年展望保守,假設 WATCHMAN 與 EP 市場無改善,且有新競爭進入。
    • Q: 2028 年恢復成長的信心來源?PFA 新競爭者影響?
      A: 2028 年成長動能來自 Interventional Cardiology、Vascular、Penumbra 等事業群高於市場成長,MedSurg 事業群回到市場均值,CRM 有新平台上市,WATCHMAN 與 EP 產品週期改善。PFA 新競爭者會有壓力,但自家產品線升級有信心。
    • Q: 內部如何銜接 2027-2028?重組進度?Penumbra 併購進度?
      A: 已啟動重組計畫,聚焦組織精簡、供應鏈優化、後勤轉型與費用控管,預計三年節省超過 5 億美元,2027 年底前達成一半。Penumbra 併購預計 2027 年初完成,雙方協同效益明顯。
    • Q: MedSurg 事業群展望?Urology、Endoscopy、Neuro 未來成長動能?
      A: Neuromodulation 表現佳,Pain 與 Brain 產品線持續推動成長。Endoscopy 受中國價格壓力,2027 年後有望回升。Urology 2027 年預期改善,Stone 產品新上市,Axonics 整合進度提升。中長期目標回到 7-8% 成長。
    • Q: 產品線時程延後原因?預測流程如何改善?
      A: 部分產品延後主因為設計驗證、FDA 溝通、供應鏈等複合因素。預測流程已強化情境分析、客觀模型與第三方數據,提升準確度。

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • -- Boston Scientific Third Quarter 2026 Earnings Call. (Operator Instructions) Please note this event is being recorded.

    -- 波士頓科學 2026 年第三季財報電話會議。(接線員指示)請注意,本活動將被錄音。

  • I would now like to turn the conference over to Lauren Tengler, Vice President, Investor Relations. Please go ahead.

    現在我想把電話會議交給投資人關係副總裁 Lauren Tengler。請開始。

  • Lauren Tengler - Vice President, Investor Relations

    Lauren Tengler - Vice President, Investor Relations

  • Thank you, Drew, and thanks to everyone for joining us. With me today are Mike Mahoney, Chairman and Chief Executive Officer; and Jon Monson, Executive Vice President and Chief Financial Officer. During the Q&A session, Mike and Jon will be joined by Joe Fitzgerald, Executive Vice President and Group President, Cardiology; and our Chief Medical Officer, Dr. Ken Stein.

    謝謝你,Drew,也感謝各位加入我們。今天與我一同出席的有:董事長兼執行長 Mike Mahoney;以及執行副總裁兼財務長 Jon Monson。在問答環節中,Mike 與 Jon 也將與執行副總裁暨心臟科事業群總裁 Joe Fitzgerald,以及我們的首席醫療長 Ken Stein 醫師一同回答問題。

  • We issued a press release earlier this morning announcing our Q3 2026 results, which included reconciliations of the non-GAAP measures used in this release. The release as well as reconciliations of the non-GAAP measures used in today's call can be found on the Investor Relations section of our website.

    我們今天稍早發布新聞稿,公布 2026 年第三季(Q3)業績,其中包含本新聞稿所使用之非 GAAP 指標的調節表。該新聞稿以及今日電話會議所使用之非 GAAP 指標調節表,可於我們網站的投資人關係專區查閱。

  • Please note that on the call, operational revenue excludes the impact of foreign currency fluctuations, and organic revenue further excludes certain acquisitions and divestitures for which there is less than a full period of comparable net sales. Guidance excludes our previously announced agreement to acquire Penumbra, which we expect to close in early 2027. For more information, please refer to the Q3 financial and operating highlights deck, which may be found on the Investor Relations section of our website.

    請注意,在本次電話會議中,營運收入(operational revenue)不包含外匯匯率波動的影響,而有機收入(organic revenue)則進一步排除某些併購與處分案的影響,因其可比淨銷售額未滿完整可比期間。本次財測不包含我們先前宣布的收購 Penumbra 協議,我們預期將於 2027 年初完成交割。更多資訊請參閱第三季財務與營運重點簡報,可於我們網站的投資人關係專區取得。

  • On this call, all references to sales and revenue are organic and relative growth is compared to the same quarter of prior year, unless otherwise specified. This call contains forward-looking statements regarding, among other things, our financial performance, business plans market expectations and product performance and development. These statements are based on our current beliefs using information available to us as of today's date and not intended to be guarantees of future events or performance.

    在本次電話會議中,除非另有說明,所有對銷售與營收的提及皆為有機口徑,且相對成長係與去年同期相比。本次電話會議包含前瞻性陳述,內容涉及(但不限於)我們的財務表現、業務計畫、市場預期,以及產品表現與開發。這些陳述係基於我們目前的信念,並使用截至今日我們可取得的資訊,且不意圖作為對未來事件或表現的保證。

  • If our underlying assumptions turn out to be incorrect or certain risks or uncertainties materialize, actual results could vary materially from those projected by the forward-looking statements. Factors that may cause such differences are discussed in the earnings release we issued earlier this morning and our periodic reports and other filings with the SEC, including the Risk Factors section of our most recent annual report on the Form 10-K.

    若我們的基本假設被證明不正確,或某些風險或不確定性發生,實際結果可能與前瞻性陳述所預期者有重大差異。可能導致此類差異的因素,已於我們今天稍早發布的財報新聞稿,以及我們向美國證券交易委員會(SEC)提交的定期報告與其他申報文件中討論,包括我們最近一期 Form 10-K 年報中的「風險因素」章節。

  • Boston Scientific disclaims any intention or obligation to update these forward-looking statements, except as required by law. In addition, this call does not constitute an offer to sell or the solicitation of an offer to buy any securities or solicitation of any vote or approval in connection with the proposed transaction with Penumbra. Boston Scientific has filed with the SEC a registration statement on Form S-4 containing a proxy statement of Penumbra and a prospectus of Boston Scientific that contains important information about Penumbra, Boston Scientific, the proposed transaction and related matters.

    除法律要求外,波士頓科學不承擔更新這些前瞻性陳述的任何意圖或義務。此外,本次電話會議不構成出售要約或購買要約之招攬,亦不構成就與 Penumbra 擬議交易相關之任何表決或核准的招攬。波士頓科學已向 SEC 提交 Form S-4 登記聲明,其中包含 Penumbra 的委託書(proxy statement)以及波士頓科學的公開說明書(prospectus),載有關於 Penumbra、波士頓科學、擬議交易及相關事項的重要資訊。

  • At this point, I'll turn it over to Mike.

    接下來,我把時間交給 Mike。

  • Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

    Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

  • Thanks, Lauren. Thank you, everyone, for joining us today. I want to begin by walking through our third quarter results, provide some fourth quarter outlook and then assumptions behind our updated view of 2027. I'll then provide more details on both the region and business unit performance and outlook.

    謝謝你,Lauren。也謝謝各位今天加入我們。我想先帶各位回顧第三季業績,提供一些第四季展望,並說明我們更新後對 2027 年的看法及其背後假設。接著我會更詳細說明各地區與各事業單位的表現與展望。

  • Q3 total company organic sales grew 1.5% versus originally guided 3% to 5%. Q3 adjusted EPS of $0.73 declined 3% versus our guidance range of $0.80 to $0.82. Our Q3 results were impacted by our previously reported cybersecurity incident, which we estimate reduced our sales growth by approximately 300 basis points and adjusted EPS by $0.07 in the quarter.

    第三季公司整體有機銷售額成長 1.5%,低於原先指引的 3% 至 5%。第三季調整後每股盈餘(adjusted EPS)為 0.73 美元,較我們 0.80 至 0.82 美元的指引區間下降 3%。我們第三季業績受到先前已通報的資安事件影響;我們估計該事件使本季銷售成長率降低約 300 個基點,並使調整後 EPS 減少 0.07 美元。

  • Importantly, after a two week outage as a result of the cyber incident, all operations are back up and running as of September 8. I'm very proud of our team's resiliency and the efforts they made to help us return as quickly as possible to supporting physicians and their patients for their products.

    重要的是,因資安事件造成兩週停擺後,截至 9 月 8 日所有營運已全面恢復並正常運作。我為團隊的韌性以及他們為了盡快恢復、以持續支援醫師與其病患使用我們產品所付出的努力感到非常自豪。

  • Turning to Q4. We anticipate that there will be a 200 to 300 basis points of impact from the cyber incident as we work through elevated customer orders at the end of Q3 to replenish inventory levels. Additionally, since our second quarter earnings call, EP share pressure has intensified further accelerated by the cyber incident. We have also seen pricing dynamics in China become more challenging.

    談到第四季。我們預期資安事件仍將帶來 200 至 300 個基點的影響,因為我們需要消化第三季末為補回庫存水位而出現的較高客戶訂單。此外,自第二季財報電話會議以來,電生理(EP)市占壓力進一步加劇,且資安事件使其加速。我們也看到中國的定價態勢變得更具挑戰。

  • To that end, we are guiding to organic revenue declines of minus 1% to minus 3% for fourth quarter '26 and adjusted EPS of $0.77 to $0.79. This results in a full year '26 organic revenue growth guide of approximately 4% and EPS of $3.16 to $3.18. Boston Scientific has enjoyed several years of exceptional growth, driven by strategic investments and strong execution globally, particularly within our EP and WATCHMAN franchises. In '26, we've seen that cycle turn, and those two businesses are now weighing on our total company growth as we navigate competition and market dynamics.

    因此,我們對 2026 年第四季的指引為:有機營收年增率下滑 -1% 至 -3%,調整後 EPS 為 0.77 至 0.79 美元。由此推算,2026 全年有機營收成長指引約為 4%,EPS 為 3.16 至 3.18 美元。波士頓科學過去數年在策略性投資與全球強勁執行力的帶動下,享有卓越成長,尤其是在我們的 EP 與 WATCHMAN 產品線。在 2026 年,我們看到該循環出現轉折,這兩項業務在我們因應競爭與市場動態之際,正對公司整體成長造成拖累。

  • We believe that 2027 will be the trough in the cycle, and we have several investments and new innovations coming over the course of the next three years that we expect will support stabilization and growth for both the EP and WATCHMAN businesses. And while the remaining 75% of our business has grown consistently, we anticipate there will be additional price headwinds in China in '27 and the growth likely won't be enough to offset the pressure from EP and WATCHMAN next year. As a result, we believe we'll be challenged to grow sales and adjusted EPS in '27, excluding our pending acquisition of Penumbra.

    我們認為 2027 年將是此循環的谷底;未來三年我們將有多項投資與新創新陸續推出,預期可支撐 EP 與 WATCHMAN 兩項業務的穩定與成長。雖然其餘 75% 的業務持續穩健成長,但我們預期 2027 年中國仍將面臨額外的價格逆風,而該成長幅度可能不足以抵消明年 EP 與 WATCHMAN 的壓力。因此,在不計入我們尚待完成的 Penumbra 收購案下,我們認為 2027 年在銷售與調整後 EPS 成長方面將面臨挑戰。

  • Having said all that, we are taking immediate actions to prepare for the future including through our previously announced restructuring program and the evolution of our operating structure while ensuring that we continue to make the right strategic investments across a number of growth platforms. We have a very strong cadence of launches in '27 and '28, and anticipate entering several new markets over the next few years that will unlock $25 billion in new market opportunity by 2030.

    儘管如此,我們正立即採取行動為未來做準備,包括透過先前宣布的重整計畫,以及營運架構的演進,同時確保我們持續在多個成長平台上進行正確的策略性投資。我們在 2027 與 2028 年有非常強勁的產品上市節奏,並預期未來幾年將進入數個新市場,至 2030 年可解鎖 250 億美元的新市場機會。

  • Importantly, we expect these actions to drive meaningful improvement in both our revenue and adjusted EPS performance as we aim to exit the cycle in '27 and return to delivering high performance in '28 with further improvement expected in '29.

    重要的是,我們預期這些行動將在營收與調整後 EPS 表現上帶來顯著改善;我們的目標是在 2027 年走出此循環,並於 2028 年恢復高績效表現,且預期 2029 年將進一步改善。

  • I'll now provide some more details on Q3 and full year '26. Turning to our regional performance. The US was flat year-over-year on an operational basis, driven by ICVT, IO&E and Neuromodulation. Europe, Middle East and Africa grew 6% on an operational basis with strong performance across many of our businesses. But within the quarter, there was some impact from cyber, offset by a transient headwind in third quarter '25 from our ERP platform go-live.

    接下來我將提供更多關於第三季與 2026 全年的細節。先看各地區表現。美國以營運口徑計算年對年持平,主要由 ICVT、IO&E 與神經調控(Neuromodulation)帶動。歐洲、中東與非洲以營運口徑計算成長 6%,我們多項業務表現強勁。但在本季中,仍受到資安事件的一些影響;同時,去年第三季因 ERP 平台上線所造成的短期逆風,對本季形成抵銷效果。

  • Asia Pacific declined 1% operationally with growth impacted by the cyber incident as well as price pressure in China. Pricing dynamics in China continue to evolve in a number of our businesses seeing VBP and other pricing impacts as a result. We expect growth in this market will moderate to single-digit growth.

    亞太地區以營運口徑計算下滑 1%,成長受到資安事件以及中國價格壓力影響。中國的定價態勢在我們多項業務中持續演變,出現 VBP 與其他定價影響。我們預期該市場的成長將放緩至個位數成長。

  • Turning to our business units. I'll start with Neuromodulation. Sales grew 13%. In Pain, growth was broad-based across the portfolio with exceptional performance with our Nalu PNS technology. But within the quarter, data was presented from the IMPROVE study evaluated in our Intracept technology with real-world outcomes showing improvements in pain function and quality of life at three months. In Brain, growth was driven by our Cartesia X lead and Illumina 3D software, which enable more precise placement and programming.

    接下來談我們的事業單位。我先從神經調控(Neuromodulation)開始。銷售額成長 13%。在疼痛(Pain)領域,成長動能遍及整體產品組合,其中我們的 Nalu PNS 技術表現尤為出色。此外,在本季中,針對我們 Intracept 技術所進行的 IMPROVE 研究公布了數據;真實世界結果顯示,在三個月時點,疼痛功能與生活品質均有所改善。在腦部(Brain)領域,成長主要由 Cartesia X 電極導線與 Illumina 3D 軟體帶動,這些產品可實現更精準的植入定位與程式設定。

  • Urology declined 3% this quarter with impact from the cyber incident as well as expanding pricing pressure in China. In stone management, we have received a number of approvals for key products, including FDA clearance of our Navigator Flex suction sheath, CE Mark and FDA clearance for distribution of the 7.5 Slim scope and FDA clearance of our LithoVue Elite single-use ureteroscope.

    泌尿科(Urology)本季下滑 3%,受到網路事件影響,以及中國日益加劇的價格壓力所致。在結石管理(stone management)方面,我們已取得多項關鍵產品核准,包括 FDA 核准我們的 Navigator Flex 抽吸鞘管、7.5 Slim 內視鏡的 CE 認證與 FDA 核准上市,以及 LithoVue Elite 一次性輸尿管鏡的 FDA 核准。

  • As we look forward, we expect these new stone launches as well as stabilization and productivity from our S&M commercial organization to help our Urology improve its growth profile over the course of 2027. Endoscopy sales declined 1% versus Q3 '25, inclusive of an impact from China VBP and cyber. Importantly, the underlying performance of this business continues to be strong, led by AXIOS, our differentiated technology, and as we look ahead, we expect our Endoscopy performance to be slightly pressured closer to mid-single-digit market growth into an annualized impact from the China VBP in fourth quarter '27.

    展望未來,我們預期這些新的結石產品上市,以及我們銷售與行銷(S&M)商業組織的穩定與生產力提升,將在 2027 年期間逐步改善泌尿科的成長輪廓。內視鏡(Endoscopy)銷售額較 2025 年第三季下滑 1%,其中包含中國 VBP 與網路事件的影響。重要的是,該業務的基本面表現仍然強勁,主要由 AXIOS(我們具差異化的技術)帶動;展望未來,我們預期內視鏡表現將因中國 VBP 在 2027 年第四季形成的年化影響而略受壓力,接近中個位數的市場成長水準。

  • Cardiovascular sales delivered growth of 2% and Interventional Cardiology and Vascular Therapies sales grew 12%. Our Interventional Cardiology business had another exceptional quarter, growing 19% with continued strength in our global imaging franchise and drug-eluting technologies. We had another outstanding quarter of our AGENT DCB, which is backed by strong clinical evidence and now has been used to treat over 400,000 patients to date.

    心血管(Cardiovascular)銷售額成長 2%,而介入性心臟病學(Interventional Cardiology)與血管治療(Vascular Therapies)銷售額成長 12%。我們的介入性心臟病學業務再度繳出亮眼一季,成長 19%,主要受惠於全球影像產品線與藥物塗層技術的持續強勁表現。AGENT DCB 也再度迎來出色的一季;該產品有強而有力的臨床證據支持,迄今已用於治療超過 400,000 名患者。

  • We remain focused on both the near- and longer-term growth opportunities for this business. And last quarter, we received IDE approval of the VITAL PCI trial that is studied in our vitals circuitry support technology in the high-risk PCI population. However, considering the evolu -- evolving clinical evidence in this space, we've made the decision to shift our strategy and focus our development and clinical efforts on the AMI cardiogenic shock indication, we believe that our device design has the potential to be well suited to treat patients experiencing cardiogenic shock and look forward to initiating clinical efforts in '27.

    我們仍聚焦於此業務的短期與長期成長機會。而在上一季,我們取得 VITAL PCI 試驗的 IDE 核准,該試驗研究我們的 VITALS 循環支持技術在高風險 PCI 族群中的應用。然而,考量此領域不斷演進的臨床證據,我們已決定調整策略,將研發與臨床資源聚焦於 AMI 心因性休克(cardiogenic shock)適應症;我們相信我們的裝置設計具備潛力,能更適切地治療正在經歷心因性休克的患者,並期待於 2027 年啟動臨床工作。

  • Our VITALYST program is one of the largest internal R&D programs and an important long-term growth driver. To solidify funding for the AMI shock program, we have entered an agreement with Blackstone Life Sciences and aim to bring this important technology to market in 2030.

    我們的 VITALYST 計畫是公司內部規模最大的研發(R&D)計畫之一,也是重要的長期成長驅動因素。為了鞏固 AMI 休克計畫的資金來源,我們已與 Blackstone Life Sciences 達成協議,目標是在 2030 年將這項重要技術推向市場。

  • Our Vascular Therapies business grew 1% with some impact from cyber as well as TCAR supply constraints Importantly, we anticipate that our TCAR supply to improve throughout fourth quarter with full resolution by early next year. Our seismic launch continues to go well. And within the quarter, we received FDA clearance for SEISMIQ IVL -- sorry, SEISMIQ IVL to treat patients with severely calcified peripheral artery disease in small vessel, expanding our size matrix to now treat above the knee and below the knee. We also received FDA approval for the Ranger 035 drug-coated balloon, offering an expanded size and providing a highly complementary offering as most IVL procedures that are performed in lower limbs are also followed by drug-eluting technologies.

    我們的血管治療(Vascular Therapies)業務成長 1%,受到網路事件以及 TCAR 供應限制的部分影響。重要的是,我們預期 TCAR 供應將在第四季逐步改善,並於明年初完全解決。我們的 Seismic 產品上市進展持續良好。此外,在本季中,我們取得 FDA 核准 SEISMIQ IVL——抱歉,是 SEISMIQ IVL——用於治療小血管中嚴重鈣化的周邊動脈疾病患者,擴展了我們的尺寸矩陣,現可治療膝上與膝下病灶。我們也取得 Ranger 035 藥物塗層球囊(drug-coated balloon)的 FDA 核准,提供更完整的尺寸選擇,並形成高度互補的產品組合,因為多數下肢進行的 IVL 手術後也會接續使用藥物塗層技術。

  • We remain excited about the opportunity to add Penumbra team to the -- we are excited about the opportunity to add the Penumbra team, and their highly differentiated in the complementary portfolio to Boston Scientific. We continue to work with the regulators and now expect to close in early '27, subject to the receipt of the remaining regulatory clearances.

    我們對於將 Penumbra 團隊納入——我們對於將 Penumbra 團隊及其在互補產品組合中高度差異化的能力納入波士頓科學(Boston Scientific)的機會,仍感到非常振奮。我們持續與監管機關合作,目前預期在 2027 年初完成交易,惟仍須取得其餘監管核准。

  • Our Interventional Oncology & Embolization business grew 5% driven by strong performance in our cancer therapies franchise, partially offset by some supply constraints that we anticipate will be resolved in early 2027. We continue to see strong adoption of any day dosing on TheraSphere 360 as well as momentum with our Hepatic Artery Infusion technology, providing a portfolio of options for cancer treatment.

    我們的介入腫瘤與栓塞(Interventional Oncology & Embolization)業務成長 5%,主要由癌症治療產品線的強勁表現帶動,但部分被供應限制所抵銷;我們預期該供應限制將於 2027 年初解除。我們持續看到 TheraSphere 360 的「任何一天給藥」(any day dosing)獲得強勁採用,同時肝動脈灌注(Hepatic Artery Infusion)技術也持續累積動能,為癌症治療提供多元的產品選項。

  • Cardiac Rhythm Management sales declined minus 2% with some impact from the cyber incident as we navigated usage and activation of technologies that leverage remote monitoring while our systems were down. In Q3, our Diagnostics franchise grew high single digits. Our low-voltage business declined mid-single digits and high-voltage business declined low single digits. We anticipate that our performance will improve over the course of '27 with new launches and ongoing momentum.

    心律管理(Cardiac Rhythm Management)銷售額下滑 2%,部分受到網路事件影響;在系統停擺期間,我們在使用與啟用依賴遠端監測的技術時面臨挑戰。在第三季,我們的診斷(Diagnostics)產品線成長達高個位數。低電壓(low-voltage)業務下滑中個位數,高電壓(high-voltage)業務下滑低個位數。我們預期隨著新產品上市與動能延續,2027 年期間表現將逐步改善。

  • Before I turn to WATCHMAN and EP, I want to acknowledge the pressures in these two businesses and the impact that it has on our overall growth. We are acting now to strengthen the LAC market and focus our EP resources where we can compete most effectively while investing in innovation that we believe can improve over time.

    在我談 WATCHMAN 與電生理(EP)之前,我想先說明這兩項業務所面臨的壓力,以及其對我們整體成長的影響。我們正採取行動以強化 LAC 市場,並將 EP 資源聚焦於我們最能有效競爭的領域,同時持續投資於我們相信可隨時間改善的創新。

  • On WATCHMAN, sales declined minus 6%, declining to 7% in the US and growing 4% internationally. Within the US, concomitant procedures grew approximately 35% and stand-alone procedures declined high teens versus third quarter '25. We continue to believe that the overall LAC market slowdown primarily reflects changes in patient identification and referral patterns as physicians assess the clinical evidence published over the last year.

    在 WATCHMAN 方面,銷售額下滑 6%,其中美國下滑 7%,國際市場成長 4%。在美國,同期手術(concomitant procedures)約成長 35%,而單獨手術(stand-alone procedures)相較 2025 年第三季下滑達十幾個百分點(high teens)。我們仍認為,整體 LAC 市場放緩主要反映患者辨識與轉診模式的變化,因醫師正在評估過去一年所發表的臨床證據。

  • Importantly, we are executing against our investment priorities that we laid out in our 2Q call. We held over 200 Med Ed events in second quarter and third quarter, providing an opportunity for more than 2,000 referrers and implanters to gain a deeper understanding of the clinical evidence available. We've added more dedicated commercial resources to WATCHMAN to support both concomitant and standalone procedures and support the referral pathway.

    重要的是,我們正依照在第二季(2Q)電話會議中所提出的投資優先事項持續執行。我們在第二季與第三季舉辦了超過 200 場醫學教育(Med Ed)活動,讓超過 2,000 位轉診醫師與植入醫師有機會更深入理解現有的臨床證據。我們也為 WATCHMAN 增加更多專職商業資源,以同時支援同期與單獨手術,並強化轉診流程。

  • In the third quarter, we saw increased patient engagement, further reinforcing the strong demand for alternatives to oral anticoagulation and highlighting the significant unmet need of my patients who can't, shouldn't or won't take lifelong OAC. We continue to believe that focusing on these priorities will support our improvement in the LAC market over time.

    在第三季,我們看到患者參與度提升,進一步印證市場對口服抗凝血藥(oral anticoagulation)的替代方案具有強勁需求,也凸顯了那些無法、不應或不願終身服用 OAC 的患者仍存在顯著未被滿足的需求。我們仍相信,聚焦這些優先事項將隨時間推進,支持我們在 LAC 市場的改善。

  • With our third quarter performance largely in line with expectations despite the cyber incident, we are maintaining our previous outlook for our WATCHMAN business. In fourth quarter, within the US, we anticipate no improvement in the year-over-year stand-alone procedure performance and continued deceleration in concomitant procedure growth against the very high baseline. Internationally, we anticipate similar performance in Q3 and Q4, resulting in sequential flat low single-digit declines versus Q3 '26 globally.

    儘管發生網路事件,我們第三季表現大致符合預期,因此我們維持先前對 WATCHMAN 業務的展望。在第四季,就美國而言,我們預期單獨手術的年對年表現不會改善,且在非常高的比較基期下,同期手術成長將持續放緩。在國際市場方面,我們預期第三季與第四季表現相近,使得 2026 年第三季相較之下,全球呈現連續持平至低個位數下滑。

  • Turning to '27. We believe our investments along with the potential label change will improve the market over time. However, until we see the market improve, we are assuming that the market performance will be similar to Q4 with additional pressure due to a new competitive launch. We believe in the benefit of this therapy and continue to innovate and invest for the future. And within the quarter, we commenced enrollment in the Elite AF clinical trial to evaluate the safety and effectiveness of the next-generation WATCHMAN Elite platform.

    接著談 2027 年。我們相信,我們的投資以及潛在的標籤(label)變更將隨時間推進改善市場。然而,在我們看到市場改善之前,我們假設市場表現將與第四季相近,並因新的競品上市而承受額外壓力。我們相信此療法的效益,並將持續創新與投資以布局未來。此外,在本季中,我們已開始招募 Elite AF 臨床試驗受試者,以評估下一代 WATCHMAN Elite 平台的安全性與有效性。

  • We anticipate bringing this fourth-generation technology to market in '29. And additionally, we look forward to the late-breaking data presentation of our SIMPLAAFY trial at TCT, studying post-implant drug therapy using WATCHMAN Flex Pro in assessing whether a less intensive drug regimen may help mitigate post-implant bleeding risk.

    我們預期將於「29 年」把這項第四代技術推向市場。此外,我們也期待在 TCT 上發表 SIMPLAAFY 試驗的最新數據,該試驗使用 WATCHMAN Flex Pro 研究植入後藥物治療,以評估較不密集的用藥方案是否有助於降低植入後出血風險。

  • Turning to EP. Sales declined 5% with a decline of 8% in the US and 2% growth internationally. We estimate that the cyber incident contributed to roughly half our miss primarily within our international region. But within the quarter, we continue to expand our OPAL footprint and drive more utilization of our mapping systems with our FARAWAVE and FARAPOINT catheters.

    接著談電生理(EP)。銷售額下滑 5%,其中美國下滑 8%,國際市場成長 2%。我們估計,資安事件約占我們未達標幅度的一半,主要發生在國際區域。但在本季內,我們持續擴大 OPAL 的佈局,並透過 FARAWAVE 與 FARAPOINT 導管,推動我們標測系統的更多使用。

  • The EP market has transformed over the past few years, led by our differentiated FARAPULSE platform. We have seen our strong market share position erode as new technologies are introduced and adoption of these different PFA form factors has been highly dynamic.While the cyber incident has accelerated some of the share shift, we do expect continued erosion of our PFA share position until we launched FARAWAVE Ultra, now expected in early '28, we expect our EP performance to meaningfully improve in '28 as we expand our PFA ecosystem with 2D ICE in the second half of '27 and FARAWAVE Ultra in '28 and FARAFLEX, our wide-area focal catheter in '29.

    過去幾年 EP 市場已發生轉變,並由我們具差異化的 FARAPULSE 平台帶動。隨著新技術導入,以及不同 PFA 形式因子的採用高度動態,我們原本強勁的市占地位已出現流失。雖然資安事件加速了部分市占移轉,但我們確實預期在推出 FARAWAVE Ultra 之前(目前預計於「28 年」初推出),我們的 PFA 市占地位仍將持續下滑;隨著我們在「27 年」下半年導入 2D ICE、於「28 年」推出 FARAWAVE Ultra、並於「29 年」推出 FARAFLEX(我們的廣域焦點導管)以擴大 PFA 生態系,我們預期 EP 表現將在「28 年」顯著改善。

  • In the near term, we're focusing our teams where we know we can win. We have the most utilized and studied technology for de novo A fibrillation procedures with our FARAWAVE catheters. We have a differentiated portfolio available, including our VersaCross transseptal needle and WATCHMAN technology, and we continue to invest to bring differentiated innovation to this large and fast-growing market.

    短期內,我們將團隊聚焦在我們確知能取勝的領域。在初次(de novo)心房顫動手術方面,我們的 FARAWAVE 導管是使用最廣、研究最充分的技術。我們擁有具差異化的產品組合,包括 VersaCross 經房間隔穿刺針與 WATCHMAN 技術,並持續投資,為這個龐大且快速成長的市場帶來具差異化的創新。

  • In closing, I want to restate that I remain very confident in Boston Scientific's long-term outlook. We operate in attractive markets with approximately 75% of our business, historically growing approximately 6% for many quarters. We have an impactful cadence of future growth catalysts anticipated in '27 and '28 that we expect to drive meaningful improvement to our growth profile in '28 and beyond. We remain focused on execution and delivering our updated '26 guidance, taking appropriate action to evolve our organization that will create greater focus, speed and accountability, while ensuring we are continuing to invest in our long-term growth drivers.

    最後,我想再次強調,我對波士頓科學的長期前景仍然非常有信心。我們約 75% 的業務位於具吸引力的市場,這些市場在過去多個季度的歷史成長率約為 6%。我們預期在「27 年」與「28 年」將有一系列具影響力的未來成長催化劑,並預期在「28 年」及之後顯著改善我們的成長輪廓。我們仍專注於執行並達成更新後的「26 年」指引,採取適當行動以推動組織演進,提升聚焦度、速度與問責,同時確保我們持續投資於長期成長驅動因素。

  • I'm incredibly grateful to our global employees for their resiliency and winning spirit and across all of our businesses and regions, I've seen our colleagues step up in extraordinary ways, adapting quickly and supporting one another and doing what it takes to ensure we are focused on what matters, improving patient lives through a relentless pursuit of innovation.

    我非常感謝我們全球員工的韌性與必勝精神;在我們所有事業與各個地區,我都看到同仁以非凡的方式挺身而出,快速適應、彼此支援,並竭盡所能確保我們聚焦於最重要的事——透過對創新的不懈追求來改善病患生活。

  • With that in hand, I'll hand over to Jon to provide more details.

    接下來,我把時間交給 Jon,請他提供更多細節。

  • Jonathan Monson - Chief Financial Officer, Executive Vice President

    Jonathan Monson - Chief Financial Officer, Executive Vice President

  • Thanks, Mike. Before I provide details on our third quarter financial performance, I want to express my gratitude to our customers, physicians and employees for their patience and partnership as we work through the recent cyber incident. I'm very proud of our global teams who have worked diligently to restore operations and continue to support our customers and the patients that they serve. The cyber incident caused significant disruption to our business operations and it materially impacted our third quarter financial results. Despite these challenges, we remain focused on taking the necessary actions to drive improved financial performance.

    謝謝你,Mike。在我說明第三季財務表現的細節之前,我想對我們的客戶、醫師與員工表達感謝,感謝大家在我們處理近期資安事件期間的耐心與合作。我也為我們全球團隊感到非常自豪,他們一直勤奮努力恢復營運,並持續支援我們的客戶及其服務的病患。這起資安事件對我們的業務營運造成重大干擾,並對第三季財務結果產生實質影響。儘管面臨這些挑戰,我們仍專注於採取必要行動,以推動財務表現改善。

  • So turning now to the quarter. Third quarter consolidated revenue of $5.138 billion represents 1.5% reported growth versus third quarter 2025 and includes a neutral impact from foreign exchange which was in line with expectations. As a result, operational and organic revenue growth were also 1.5% in the quarter, below our third quarter guidance range of 3% to 5%.

    接著談本季表現。第三季合併營收為 51.38 億美元,較 2025 年第三季的公告成長率為 1.5%,其中匯率影響為中性,符合預期。因此,本季營運與有機營收成長率也均為 1.5%,低於我們第三季指引區間的 3% 至 5%。

  • We estimate the cyber incident had a net negative impact of approximately 300 basis points on third quarter organic revenue growth. This impact reflects the eight business day disruption to our global network during which we were unable to manufacture or ship product, partially offset by revenue recovered as operations resumed.

    我們估計,資安事件對第三季有機營收成長率造成約 300 個基點的淨負面影響。此影響反映我們全球網路中斷 8 個營業日,期間我們無法製造或出貨產品;隨著營運恢復,部分營收回補,對影響有所抵銷。

  • Third quarter 2026 adjusted earnings per share of $0.73 declined 3% versus 2025, below our third quarter guidance range of $0.80 to $0.82. As Mike mentioned, third quarter results include an approximate $0.07 unfavorable impact from the cyber incident primarily driven by lower-than-expected sales and the additional manufacturing and operation -- operating costs associated with the cyber incident.

    2026 年第三季調整後每股盈餘為 0.73 美元,較 2025 年下滑 3%,低於我們第三季指引區間的 0.80 至 0.82 美元。如 Mike 所提,第三季結果包含資安事件約 0.07 美元的不利影響,主要由低於預期的銷售,以及與資安事件相關的額外製造與營運——營運成本所致。

  • Adjusted gross margin for the third quarter was 68.0% representing a 300 basis points decrease versus the third quarter of 2025, primarily driven by unfavorable manufacturing absorption during the cyber-related disruption. Third quarter adjusted operating margin was 26.5%, contracting 150 basis points versus the third quarter of 2025, primarily driven by the impact of the cyber incident on gross margin. On a GAAP basis, third quarter operating margin was 16.1%. These results include an approximate $80 million charge primarily related to certain product liability cases.

    第三季調整後毛利率為 68.0%,較 2025 年第三季下降 300 個基點,主要由資安相關中斷期間不利的製造吸收所致。第三季調整後營業利益率為 26.5%,較 2025 年第三季收縮 150 個基點,主要由資安事件對毛利率的影響所致。按 GAAP 基礎,第三季營業利益率為 16.1%。上述結果包含約 8,000 萬美元費用,主要與特定產品責任案件相關。

  • Moving to below the line. Third quarter adjusted interest and other expenses totaled $124 million, which was in line with expectations. On an adjusted basis, our tax rate for the third quarter was 14.3%, which was higher than expected due to certain discrete tax items. Fully diluted weighted average shares outstanding ended at 1.452 billion in the third quarter and free cash flow for the third quarter was $867 million, with $1.047 billion from operating activities less $180 million in net capital expenditures. As of September 30, 2026, we had cash on hand of $609 million and our gross debt leverage ratio was 1.9 times.

    接著看營業利益以下項目。第三季調整後利息及其他費用合計 1.24 億美元,符合預期。在調整後基礎上,我們第三季稅率為 14.3%,因若干一次性稅務項目而高於預期。第三季完全稀釋加權平均流通股數為 14.52 億股;第三季自由現金流為 8.67 億美元,係由營運活動現金流入 10.47 億美元扣除淨資本支出 1.80 億美元而得。截至 2026 年 9 月 30 日,我們手上現金為 6.09 億美元,總負債槓桿比率為 1.9 倍。

  • Our capital allocation approach remains disciplined and growth oriented. Our top priorities remain strategic tuck-in M&A and opportunistic share repurchases, while we continue to evaluate and fund the opportunities that we believe will create the greatest long-term value for our shareholders. We look forward to closing our acquisition of Penumbra, which we believe will strengthen our long-term growth profile through its innovative portfolio and strong strategic fit within our cardiovascular business.

    我們的資本配置方針仍維持紀律並以成長為導向。我們的首要重點仍是策略性補強型併購(tuck-in M&A)與機會性庫藏股回購;同時,我們持續評估並投入資金於我們認為能為股東創造最大長期價值的機會。我們期待完成對 Penumbra 的收購;我們相信,透過其創新產品組合,以及與我們心血管業務的高度策略契合,將強化我們的長期成長輪廓。

  • In addition to tuck-in M&A, we're leveraging strategic partnerships to advance innovation, ensuring we're directing capital towards high-growth opportunities. Consistent with this approach, we recently entered into an agreement with Blackstone Life Sciences to co-fund the development of our VITALYST circulatory support system for the treatment of patients with cardiogenic shock. Under the agreement, Boston Scientific will receive funding from Blackstone, which will be recognized as a reduction to R&D expense as the related costs are incurred.

    除補強型併購外,我們也運用策略夥伴關係推進創新,確保資本投向高成長機會。依循此一方針,我們近期與 Blackstone Life Sciences 達成協議,共同出資開發 VITALYST 循環支持系統,用於治療心因性休克患者。依據協議,波士頓科學將自 Blackstone 取得資金;在相關成本發生時,該資金將以研發費用的減項認列。

  • Upon achievement of certain milestones expected starting in 2030, Blackstone will be eligible to receive a return on the actual amount funded for the program plus royalties on sales of VITALYST. This agreement allows us to continue advancing VITALYST while accelerating investments in other high-growth opportunities.

    在達成若干里程碑後(預計自 2030 年起),Blackstone 將有資格就該計畫實際出資金額取得報酬,並就 VITALYST 的銷售取得權利金。此協議使我們得以持續推進 VITALYST,同時加速對其他高成長機會的投資。

  • Before I discuss guidance, I want to acknowledge that we need to rebuild confidence in our forecast. We've implemented meaningful enhancements to our forecasting process, which we believe provide a stronger foundation for more accurate forecasting going forward. And so now I'll walk through our guidance for the fourth quarter and full year 2026.

    在我討論指引之前,我想先承認,我們需要重建市場對我們預測的信心。我們已對預測流程進行具實質意義的強化,我們相信這將為未來更準確的預測提供更穩固的基礎。接下來,我將說明我們對第四季與 2026 全年的指引。

  • We now expect full year 2026 reported revenue growth to be approximately 4.25% versus 2025. Excluding an approximate 50 basis points tailwind from foreign exchange based on current rates, we expect full year 2026 operational and organic growth to be approximately 3.75%. We expect fourth quarter 2026 reported revenue to decline in a range of down 3% to down 1% versus fourth quarter 2025. We anticipate no impact from foreign exchange based on current rates, and therefore, expect fourth quarter 2026 operational and organic revenue to also decline in a range of down 3% to down 1%.

    我們目前預期 2026 全年報告營收成長率約為 4.25%,相較於 2025 年。若排除依目前匯率計算、約 50 個基點的外匯順風,我們預期 2026 全年營運與有機成長率約為 3.75%。我們預期 2026 年第四季報告營收相較 2025 年第四季將下滑,區間約為下滑 3% 至下滑 1%。依目前匯率,我們預期外匯不會造成影響,因此,2026 年第四季營運與有機營收亦預期將下滑,區間約為下滑 3% 至下滑 1%。

  • As Mike mentioned, our fourth quarter guidance contemplates a headwind from the cyber incident reflecting elevated customer ordering at the end of the third quarter, which we expect to normalize over the course of the fourth quarter. We expect full year 2026 adjusted gross margin to be below full year 2025, reflecting a less favorable product mix, investment in our global supply chain and quality systems and the additional impact of the cyber incident. We now expect full year 2026 adjusted operating margin to be approximately 27.6%, reflective of gross margin pressures. We continue to expect full year 2026 adjusted below the line expense to be approximately $485 million.

    如 Mike 提到的,我們的第四季指引納入了網路事件帶來的逆風,反映第三季末客戶下單量偏高,我們預期將在第四季期間逐步回歸正常。我們預期 2026 全年調整後毛利率將低於 2025 全年,原因包括較不利的產品組合、對全球供應鏈與品質系統的投資,以及網路事件的額外影響。我們目前預期 2026 全年調整後營業利益率約為 27.6%,反映毛利率壓力。我們仍預期 2026 全年調整後線下費用(below the line expense)約為 4.85 億美元。

  • Under current legislation, including enacted laws and issued guidance, we now expect a full year 2026 adjusted tax rate of approximately 12%. We expect full year 2026 free cash flow to be approximately $3.6 billion, reflecting a reduced operating income outlook. We expect full year 2026 adjusted earnings per share to be in a range of $3.16 to $3.18, representing growth of 3% to 4% versus 2025, including an approximate $0.06 headwind from foreign exchange, and we expect fourth quarter adjusted earnings per share to be in the range of $0.77 to $0.79.

    依現行法規(包括已頒布法律與已發布指引),我們目前預期 2026 全年調整後有效稅率約為 12%。我們預期 2026 全年自由現金流約為 36 億美元,反映營業利益展望下修。我們預期 2026 全年調整後每股盈餘將介於 3.16 至 3.18 美元,較 2025 年成長 3% 至 4%,其中包含外匯約 0.06 美元的逆風;我們並預期第四季調整後每股盈餘介於 0.77 至 0.79 美元。

  • As Mike outlined, we anticipate continued top line pressure into 2027, which we expect will make it challenging to grow revenue and adjusted earnings per share, excluding Penumbra. We expect our underlying business dynamics in Q4 to persist into 2027 and believe our fourth quarter guidance provides a reasonable baseline for next year's revenue and adjusted earnings per share outlook. Importantly, we're taking decisive actions to drive greater focus, speed and accountability, most notably through our company-wide restructuring program.

    如 Mike 所概述,我們預期營收端壓力將延續至 2027 年,這將使得在不含 Penumbra 的情況下,營收與調整後每股盈餘的成長更具挑戰。我們預期第四季所見的基本業務動態將延續至 2027 年,並認為我們的第四季指引為明年營收與調整後每股盈餘展望提供了合理的基準。重要的是,我們正採取果斷行動,以提升聚焦度、速度與問責,最顯著的是透過全公司範圍的重組計畫。

  • This comprehensive initiative is focused on org structure evolution, supply chain optimization, back-office transformation and reductions in other categories of spend. We expect these efforts to deliver sustained cost efficiencies while allowing us to prioritize investments that support long-term growth.

    這項全面性計畫聚焦於組織架構演進、供應鏈最佳化、後勤/後台(back-office)轉型,以及其他支出類別的削減。我們預期這些努力將帶來可持續的成本效率,同時讓我們能優先投入支持長期成長的投資。

  • In closing, we believe we're well positioned in attractive markets. We're making the right investments and taking the necessary steps to strengthen our financial performance. I'm confident that these actions will position us to stabilize Boston Scientific in 2027 and then drive improved revenue and adjusted earnings per share growth in 2028 and then further acceleration in 2029. For more information, please check our Investor Relations website for third quarter 2026 financial and operational highlights, which outlines more details on third quarter results and 2026 guidance.

    最後,我們相信我們在具吸引力的市場中具備良好定位。我們正在進行正確的投資,並採取必要步驟以強化我們的財務表現。我有信心,這些行動將使我們能在 2027 年穩定 Boston Scientific,並在 2028 年推動營收與調整後每股盈餘成長改善,且在 2029 年進一步加速。欲了解更多資訊,請至我們的投資人關係網站查閱 2026 年第三季財務與營運重點,其中提供第三季結果與 2026 年指引的更多細節。

  • And so Lauren, with that, I'll turn it back to you to moderate the Q&A.

    那麼 Lauren,接下來我把時間交還給你來主持問答。

  • Lauren Tengler - Vice President, Investor Relations

    Lauren Tengler - Vice President, Investor Relations

  • Thanks, Jon. Drew, let's open it up for questions for the next 30 minutes or so. In order for us to take as many questions as possible, please limit yourself to one question. Drew, please go ahead.

    謝謝,Jon。Drew,接下來大約 30 分鐘我們開放提問。為了讓我們能回答盡可能多的問題,請各位每人限問一題。Drew,請開始。

  • Operator

    Operator

  • (Operator Instructions) Robbie Marcus, JPMorgan.

    (接線員指示) Robbie Marcus,摩根大通(JPMorgan)。

  • Robert Marcus - Analyst

    Robert Marcus - Analyst

  • A lot to dig into. I'll stick with one here and focus on guidance. Maybe you could -- and there's a lot of questions I'm getting from investors. So hopefully, this will help clarify. How do we think about sort of the actual underlying impact from the hack disruption in third quarter? It sounds like there was some order benefits. What's the actual impact and why bleeding into fourth quarter? And with the no growth comment on 2027, how much of that is conservatism related to the hack and how much is new information of end market and product timing?

    有很多可以深入探討的地方。我這裡就只問一題,聚焦在指引。也許你可以——我從投資人那邊收到很多問題。希望這能幫助釐清。我們該如何看待第三季駭客干擾對實際基本面的影響?聽起來似乎有一些訂單面的受益。實際影響是多少?為什麼會延續到第四季?另外,關於 2027 年「不成長」的評論,其中有多少是與駭客事件相關的保守假設,又有多少是來自終端市場與產品時程的新資訊?

  • Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

    Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

  • Jon, do you want to take the cyber question?

    Jon,你要回答網路事件的問題嗎?

  • Jonathan Monson - Chief Financial Officer, Executive Vice President

    Jonathan Monson - Chief Financial Officer, Executive Vice President

  • Sure. Yes. Thanks, Robbie. So let me lay out the impacts of cyber. So in Q3, we estimate a roughly 300 basis points headwind to our revenue from cyber, so call it roughly $150 million of headwind on the top line and then bottom line impact to EPS of $0.07. So the impact of the lost sales, we did have unfavorable manufacturing absorption that contributed to the $0.07 of EPS as well as other direct costs, expedited shipping, cost of experts that impacted Q3 cyber.

    當然。是的。謝謝你,Robbie。我先說明網路事件的影響。在第三季,我們估計網路事件對營收造成約 300 個基點的逆風,換算約為營收端約 1.5 億美元的逆風;對每股盈餘(EPS)的影響為 0.07 美元。就流失銷售的影響而言,我們也出現了不利的製造吸收(manufacturing absorption),這也對 0.07 美元的 EPS 影響有所貢獻,此外還有其他直接成本、加急運輸,以及專家費用等,皆影響了第三季的網路事件成本。

  • For the fourth quarter, we expect an ongoing impact of approximately 200 to 300 basis points. And so what we saw, Robbie, coming out of the cyber incident is a level of stocking of -- from customers. And over the fourth quarter, we'll burn off some of those inventory levels. So that's why you see the ongoing impact into the fourth quarter of that 200 bps to 300 bps. And that drops through down to EPS, roughly $0.04 to $0.05 of impact in the fourth quarter.

    至於第四季,我們預期仍將持續受到約 200 至 300 個基點的影響。Robbie,我們在網路事件後看到的是客戶出現一定程度的備貨——而在第四季期間,這些庫存水位會逐步消化。因此你會看到第四季仍有 200 至 300 個基點的持續影響。這也會反映到 EPS 上,第四季影響約為 0.04 至 0.05 美元。

  • Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

    Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

  • Yes. Maybe just some comments on the '27 question. When we think about it, we obviously aim to exceed these expectations. But just to frame and we'll give our guidance, obviously, in January. We really do expect some of the underlying business dynamics that we see in the fourth quarter to persist in 2027. So if you look at that, you've got a number of our businesses doing extremely well, Interventional Cardiology, Vascular, IO&E, Endoscopy's underlying business is doing quite well despite the pressures in China.

    是的。也許我再補充一些對於「2027 年」問題的看法。我們在思考時,當然目標是超越這些預期。不過先做個框架說明——我們會在一月提供正式指引。我們確實預期第四季所見的一些基本業務動態將延續到 2027 年。因此如果你看這些動態,我們有多個事業表現非常好:介入心臟科(Interventional Cardiology)、血管(Vascular)、IO&E;內視鏡(Endoscopy)的基本業務也表現相當不錯,儘管在中國面臨壓力。

  • So the overall base business, we feel has consistently grown about 6%. We expect about a point of impact due to the comprehensive China pricing issues, and that represents about 75% of the business. So the two key areas -- questions are what will be the impact of WATCHMAN and EP in 2027? So for the basis of our early framing of guidance, we wanted to be appropriately conservative. So we're assuming that the WATCHMAN market dynamics do not improve over current state. And we're obviously doing a lot to turn that around. But those underlying markets today are growing about negative 7%, negative 8%-ish in that area. And we do have a competitive launch coming in 2027.

    因此整體基礎業務,我們認為一直以來約成長 6%。我們預期全面性的中國定價議題將帶來約 1 個百分點的影響,而這部分約占業務的 75%。因此兩個關鍵領域——問題在於 2027 年 WATCHMAN 與 EP 的影響會是什麼?就我們早期的指引框架而言,我們希望採取適度保守的假設。因此我們假設 WATCHMAN 的市場動態不會較目前狀態改善。當然,我們正在做很多工作來扭轉局面。但目前這些底層市場在該領域約為負 7%、負 8% 左右的成長。而且我們在 2027 年將面臨競品上市。

  • So the error bars are on the market around the WATCHMAN assumptions are quite wide, given that we are assuming no improvement in the market despite some of our efforts and an anticipated label change where we're assuming that the market baseline stays similar to Q4 with competitive entry in '27.Similarly, in EP, EP will be a challenging year for us in '27, and we're very optimistic about '28 and '29 based on our product launch cadence. But in '27, we are lacking new product launches. The market continues to be fairly healthy, but we expect to continue to see share in 2027 in EP, similar to the rates that we've seen in the second half of 2026.

    因此,圍繞 WATCHMAN 假設的市場不確定性區間(error bars)相當大,因為即便我們做出一些努力,且預期會有適應症標籤(label)變更,我們仍假設市場不會改善;我們假設市場基準將與第四季相近,並在 2027 年出現競爭者進入。同樣地,在 EP 方面,2027 年對我們而言將是具挑戰的一年;基於我們的產品上市節奏,我們對 2028 與 2029 年非常樂觀。但在 2027 年,我們缺乏新產品上市。市場本身仍相對健康,但我們預期在 2027 年 EP 仍將持續出現市占流失,幅度與 2026 年下半年所見的速度相近。

  • Until we successfully launch a ICE program in second half of '27, an excellent platform upgrade with FARAPULSE Ultra, ideally late fourth quarter, early first quarter, '27. And as you know, we've initiated our clinical trial FARAFLEX platform, which will be an early '29 launch. So hopefully, that gives you some context for 2027.

    在我們於「27 年下半年」成功推出 ICE 計畫之前,我們會先以 FARAPULSE Ultra 進行一次出色的平台升級,理想時點為「26 年第四季末到 27 年第一季初」。另外,如你所知,我們已啟動 FARAFLEX 平台的臨床試驗,預計將於「29 年初」上市。希望這能讓你對 2027 年有一些脈絡。

  • Operator

    Operator

  • Larry Biegelsen, Wells Fargo.

    Larry Biegelsen,富國銀行。

  • Lawrence Biegelsen - Analyst

    Lawrence Biegelsen - Analyst

  • So super helpful color on 2026 and 2027. Mike, just talk about your confidence in improving sales and EPS growth in '28. I'm not looking for specifics, obviously, but what are the drivers, it looks like FARAFLEX, the launch was pushed out to 2029 in the slides, if I'm reading that correctly. And I think there are some concerns about new PFA competition coming in '28, with the novel waveform. And so how are you factoring that in?

    關於 2026 年與 2027 年的說明非常有幫助。Mike,請談談你對於在「28 年」提升銷售與 EPS 成長的信心。我當然不是要你提供具體數字,但驅動因素是什麼?看起來如果我沒看錯投影片,FARAFLEX 的上市被延後到 2029 年。而且我認為市場也有一些疑慮,因為在「28 年」可能會有新的 PFA 競爭者進入,帶著新型波形。所以你們是如何把這些因素納入考量的?

  • Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

    Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

  • Yes. Thank you. Just a backdrop a bit and maybe not new news. '23 to '25, we experienced a very high growth cycle much on the heels of our base business being strong and the tremendous growth of our WATCHMAN and EP. We also had a decent first half despite some of our forecasting challenges growing 8% in the first half of 2026. We are clearly in the middle of a down cycle, which is a short-term phenomenon for Boston Scientific that you will see, that we predicted in fourth quarter based on our guide in 2027. We are very confident about the return to growth and kind of pushing off the bottom in '27 as we enter '28.

    是的,謝謝。先提供一些背景,可能也不是什麼新消息。從「23 年到 25 年」,我們經歷了一個非常高成長的週期,主要是因為我們的基礎業務很強,加上 WATCHMAN 與 EP 的大幅成長。儘管我們在預測上遇到一些挑戰,2026 年上半年仍有不錯表現,上半年成長 8%。我們很明顯正處於一個下行週期中,對波士頓科學而言這是一種短期現象;我們在第四季就已根據 2027 年的指引預測到這點。我們對於在「27 年」觸底回升、並在進入「28 年」時重返成長非常有信心。

  • And a high-level formula for growth in '28, potentially below our WAMGR, but solid growth and growth above our WAMGR in '29 really are the -- if you look at our three segments. Our biggest segment, as you look at 2028, will be our Interventional Cardiology, Vascular and Penumbra business. We expect that collection of businesses to comfortably grow above their market WAMGR as Penumbra goes organic and they continue to drive excellent momentum.

    而「28 年」的高層次成長公式——可能低於我們的 WAMGR,但仍是穩健成長;而在「29 年」則會高於我們的 WAMGR——主要取決於三大事業部的表現。以 2028 年來看,我們最大的事業部將是介入性心臟科、血管與 Penumbra 業務。我們預期這一組合的業務將能夠穩健地高於其市場 WAMGR 成長,因為 Penumbra 會轉為有機成長,並持續帶動極佳的動能。

  • And with a very strong portfolio cadence in that business with our IVL platforms in peripheral and vascular potentially hypertension in 2028 and a strong cadence of imaging capabilities as well as launches within our VC, IO&E platform. So that will represent our biggest segment, very much on offense growing above WAMGR and propelling the growth of the company.

    此外,該業務在產品組合節奏上非常強勁:我們的 IVL 平台在周邊與血管領域持續推進,並可能在 2028 年切入高血壓;同時影像能力也有強勁的推出節奏,並且在我們的 VC、IO&E 平台中也會有多項上市。因此,這將是我們最大的事業部,會以進攻姿態高於 WAMGR 成長,並推動公司整體成長。

  • Our MedSurg business, with a number of key launches, you saw a couple of key approvals just this quarter in our urology business. We expect our MedSurg segment businesses to essentially grow at our market WAMGR or grow at their market WAMGR, call it, mid-single digits. So then it really comes down to what happens to EP and WATCHMAN and CRM. The good news in CRM is we'll be launching a significant platform launch with Denali, our defibrillator platform, which we expect CRM will comfortably return to growth in 2028 to help that segment.

    我們的 MedSurg 業務也有多項關鍵上市;你們在本季也看到我們泌尿科業務取得了幾項重要核准。我們預期 MedSurg 事業部的各項業務基本上會以我們的市場 WAMGR 成長,或說以其各自市場的 WAMGR 成長,大約是中個位數成長。因此,關鍵就回到 EP、WATCHMAN 與 CRM 的表現。CRM 的好消息是,我們將推出一個重大的平台上市——Denali,也就是我們的去顫器平台;我們預期 CRM 在 2028 年將能夠穩健重返成長,進而支撐該事業部。

  • And then in WATCHMAN, we will anniversary a competitive launch in 2028. We'll be in the midst of a trial of our fourth-generation platform. As you know, we've got a very, very strong share in WATCHMAN, and we expect to maintain that strong leadership position during this case. We'll also aim to have a approved label change ideally by 2028. So we see the WATCHMAN business kind of maximum down is in 2027, and will return to a healthier position in 2028.

    至於 WATCHMAN,我們在 2028 年會迎來競品上市的一周年效應。我們也將處於第四代平台試驗的進行中。如你所知,我們在 WATCHMAN 擁有非常、非常強的市占率,我們預期在此期間仍能維持強勢的領導地位。我們也會力求在 2028 年前後取得核准的標籤變更(label change)。因此我們認為 WATCHMAN 業務的最大下行壓力會出現在 2027 年,並在 2028 年回到較健康的狀態。

  • Similar with our EP business, again, it's driven by portfolio and cadence. And as I mentioned before, we'll have our ICE platform launch, our full year of FARAPULSE Ultra and pending approval of Flex business. So we expect the overall Rhythm Solutions business with a stronger growth in CRM and improving cadence of effective launches in EP and WATCHMAN to significantly improve the growth profile of Rhythm in '28, whereas 2027 that segment is driving the challenges.

    我們的 EP 業務也類似,同樣是由產品組合與推出節奏所驅動。如我先前提到的,我們將有 ICE 平台上市、FARAPULSE Ultra 的完整年度貢獻,以及 Flex 業務的待核准事項。因此,我們預期整體 Rhythm Solutions 業務——在 CRM 成長更強、且 EP 與 WATCHMAN 的有效上市節奏改善之下——將在「28 年」顯著改善 Rhythm 的成長輪廓;而在 2027 年,該事業部則是造成挑戰的主要來源。

  • Operator

    Operator

  • Joanne Wuensch, Citi.

    Joanne Wuensch,花旗。

  • Joanne Wuensch - Analyst

    Joanne Wuensch - Analyst

  • Two parts. One part is, internally, it sounds like you're doing quite a bit to build the bridge between today and 2028, which could include any number of things such as sales force realignment expense reduction, et cetera, et cetera. Could you please address what you're doing internally to build that bridge? And then second of all, the Penumbra delay, is there a way to share the steps to that resolution?

    兩個部分。第一部分是,從內部來看,聽起來你們正在做不少工作來搭建從現在到 2028 年之間的「橋樑」,可能包含多種措施,例如銷售團隊重新配置、費用削減等等。能否請你們說明一下,內部正在做哪些事情來搭建這座橋?第二,Penumbra 的延遲,是否能分享一下解決該問題的步驟?

  • Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

    Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

  • Sure. We're certainly and Jon, you can comment a bit more. As you would expect, we're aligning our cost structure to a reality of what we see in fourth quarter in 2027. So the team has gotten ahead of that about six months ago and are implementing a pretty meaningful restructuring program, both in terms of where we our discretionary spend, headcount. We want to delayer the company a bit more, increase some of the spans and layers in the organization and get after some SG&A offsets. So that program is very much in flight.

    當然可以。我們確實在做,Jon 你也可以補充更多。如你所預期的,我們正在把成本結構調整到我們在 2027 年第四季所看到的現實情況。因此團隊大約在六個月前就已提前著手,並正在推動一項相當有意義的重整計畫,涵蓋我們的可自由支配支出、以及人力編制等。我們希望讓公司再更「去層級化」一些,擴大組織中的管理幅度與層級配置,並尋求一些 SG&A 的抵銷(節省)。所以這個計畫正在全面推進中。

  • Importantly, we maintain the really important cultural values of Boston Scientific that makes it a special place to work and focus on advancing science for life and our winning spirit. So we believe we will continue to drive a important culture within Boston Scientific focused on the future despite the needed restructuring initiatives.

    重要的是,我們會維持波士頓科學真正重要的文化價值——這也是讓這裡成為特別工作場所的原因——並聚焦於推進「為生命而科學(science for life)」以及我們的致勝精神。因此我們相信,即便需要推動重整措施,我們仍能在波士頓科學持續打造一個面向未來、且很重要的企業文化。

  • Importantly, while we're doing that, we're also continuing to invest in these big growth platforms that will drive the company's growth back to a decent growth in '28 and above market WAMGR and entering all these new markets that we're taking on. So I think it's important that we show the discipline to drive those cost savings and invest in our growth drivers at the same time.

    同樣重要的是,在做這些調整的同時,我們也會持續投資於這些大型成長平台;它們將帶動公司在「28 年」回到不錯的成長、並高於市場 WAMGR,且協助我們進入所有這些我們正在切入的新市場。所以我認為很重要的是,我們要同時展現紀律:一方面推動成本節省,另一方面也同步投資於成長驅動因素。

  • Jonathan Monson - Chief Financial Officer, Executive Vice President

    Jonathan Monson - Chief Financial Officer, Executive Vice President

  • And Joanne, I'd just add with the restructuring program, I'll fill in a couple of pieces there. So anticipate to achieve over $500 million of savings from the program over the next three years, been some tough decisions, but I've been very pleased with how we've been tracking. We're a little ahead of where I thought we'd be at this point in the program. I expect to achieve over half of those savings exiting 2027. So back to Larry's question, that contributes to our confidence in 2028. Mike went through the top line, but from an EPS perspective as well.

    Joanne,我再補充幾點關於重整計畫的內容。我們預期在未來三年內,該計畫可帶來超過 5 億美元的節省;這當中有一些艱難的決策,但我對我們的執行進度非常滿意。就目前這個階段而言,我們的進度比我原先預期的還要稍微超前。我預期在 2027 年結束時(exit 2027),可以實現超過一半的節省。因此回到 Larry 的問題,這也提升了我們對 2028 年的信心。Mike 談了營收端(top line),但從 EPS 的角度來看也是如此。

  • Program itself, focused on streamlining org structures, back-office transformation to streamline our processes, leverage shared services. There's a supply chain optimization looking across our global supply network, to better leverage technology, AI and streamline across supply chain and then a broader initiative just looking at other pools of spend like T&E meetings, like use of external vendors to reduce our spend there. So it's a very broad initiative, but very focused. And again, I've been pleased with how we've been tracking. We're a little ahead of our schedule there.

    這個計畫本身聚焦於精簡組織架構、推動後勤(back-office)轉型以簡化流程,並運用共享服務。也包含供應鏈最佳化:檢視我們的全球供應網路,更好地運用科技與 AI,並在供應鏈各環節進行精簡;此外還有一項更廣泛的倡議,檢視其他支出池,例如差旅與費用(T&E)、會議,以及外部供應商的使用,以降低相關支出。因此這是一項非常廣泛、但也非常聚焦的計畫。同樣地,我對我們的執行進度感到滿意。我們在時程上也略微超前。

  • Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

    Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

  • And sorry, Joanne, on the Penumbra comments, maybe some good and bad news. Overall, we're super impressed with the Penumbra results for 2026. And the good news is with a bit of an extended closing period, we've continued to get to know the Penumbra team extremely well, how they run the business, the synergies that are very obvious on growth side and some on the cost side when you combine two powerful businesses with Intervention Cardiology, Vascular in the Penumbra business.

    Joanne,不好意思,關於 Penumbra 的評論,可能有一些好消息也有一些壞消息。整體而言,我們對 Penumbra 2026 年的業績表現印象非常深刻。好消息是,因為交割期稍微延長,我們得以持續更深入了解 Penumbra 團隊、他們如何經營業務;以及當你把兩個在介入心臟科與血管領域都很強的業務(其中一個是 Penumbra 的業務)結合時,在成長端非常明顯、在成本端也有一些的綜效。

  • So we're very bullish on the Penumbra team, the progress, the innovation pipeline they have and how they will work very seamlessly within Boston Scientific to drive ongoing strength in Penumbra and our ICVT business. On the regulatory process, has taken a bit of time. We're still very confident in closing the transaction. But based on some of the discussions with the regulatory authorities, we anticipate an early first quarter close.

    因此我們對 Penumbra 團隊、其進展、他們的創新產品管線,以及他們將如何在波士頓科學內部非常順暢地運作、以推動 Penumbra 與我們 ICVT 業務的持續強勁表現,抱持非常樂觀的看法。在監管流程方面,確實花了一些時間。我們對完成交易交割仍然非常有信心。但基於與監管機關的一些討論,我們預期將在第一季初完成交割。

  • Operator

    Operator

  • Rick Wise, Stifel.

    Rick Wise,Stifel。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Mike, I was hoping maybe you could further unpack the MedSurg outlook a little bit. You said, I think, just a moment ago, you expected the combined business to grow mid-single digits sort of in line with the WAMGR market growth. But maybe talk us through each piece. Historically, these are businesses that in totality grew 7% or 8%. Why can't we dream or aspire for you to get back to that kind of range? And maybe what needs to happen in Urology, Endoscopy and Neuro to get back there? And what are the key drivers here as we look ahead to the next year or two?

    Mike,我希望你能再更深入拆解一下 MedSurg 的展望。你剛才提到,你預期合併後的業務將以中個位數成長,大致與 WAMGR 市場成長一致。但也許可以帶我們逐一看每個部分。歷史上,這些業務合計的成長率是 7% 或 8%。為什麼我們不能期待或憧憬你們回到那樣的區間?而且泌尿科、內視鏡與神經這幾塊需要發生什麼,才能回到那裡?展望未來一到兩年,這裡的關鍵驅動因素是什麼?

  • Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

    Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

  • Yes, I would agree. five to six mid-single-digit growth is not what we want MedSurg to be and not what it's been and not what the potential is. Just to break through the three of them really quickly. Neuromodulation is doing very well. Our Brain franchise is doing well. We've really diversified our Pain business into more minimally invasive alternatives in addition to spinal cord stim. And we continue to have additional growth drivers in that business with the whole new SCS launch that will happen in 2028.

    是的,我同意。5% 到 6% 的中個位數成長並不是我們希望 MedSurg 呈現的樣子,也不是它過去的表現,更不是它的潛力所在。我很快把三個部分拆開說一下。神經調控(Neuromodulation)表現非常好。我們的 Brain 產品線表現良好。除了脊髓刺激(spinal cord stim)之外,我們也把疼痛(Pain)業務多元化,擴展到更多微創替代方案。此外,隨著 2028 年將推出全新的 SCS 產品,我們在該業務上仍有額外的成長驅動因素。

  • So overall, I would assume kind of over a period of time, the Neuromod business will continue to be accretive to the MedSurg growth profile. Our Endo business is very strong. We've got a list of quite a few product launches in that area with scopes and our versatile platform and a number of others. The headwind in 2027 for Endo is China. Significant pricing erosion we will see in our China business in 2027. So the Endo business will anniversary that China pricing impact in fourth quarter 2027. So we expect kind of our Endo business to be at that mid-single-digit growth range in '27 accelerated '28 based on launching and getting -- lapping that China piece.

    因此整體而言,我會假設隨著時間推進,Neuromod 業務將持續對 MedSurg 的成長輪廓帶來增益。我們的 Endo(內視鏡)業務非常強勁。在該領域我們有相當多的產品上市計畫,包括鏡體(scopes)、我們的多功能平台,以及其他多項產品。2027 年 Endo 的逆風來自中國。我們預期 2027 年在中國業務將看到顯著的價格侵蝕。因此 Endo 業務要到 2027 年第四季才會度過(anniversary)這個中國價格影響。所以我們預期 2027 年 Endo 業務大致會落在中個位數成長區間,而 2028 年會因新品上市以及跨過(lapping)中國那一塊因素而加速。

  • The challenge, quite frankly, has been Urology. And we've been wrong on calling the growth trend in Urology. Obviously, a lot of efforts are going on in that area. So we expect the Urology business to improve in 2027, not back to its previous levels, but certainly not at a negative growth profile that we see in 2026. And this business is all about people and portfolio. We just announced in our script there, we've got three Stone launches that -- or, three Stone approvals, which has been the one segment that's been lagging the growth for that franchise. So we expect our core Stone business to improve in 2027.

    坦白說,挑戰一直在泌尿科(Urology)。而且我們對泌尿科的成長趨勢判斷一直有誤。顯然,我們在那個領域正在進行很多努力。因此我們預期 2027 年泌尿科業務會改善,雖然不會回到先前的水準,但肯定不會像 2026 年那樣呈現負成長。這個業務的關鍵在於人才與產品組合。我們剛才在講稿中也宣布,我們有三項結石(Stone)產品上市——或者說三項結石產品核准——而結石一直是該產品線成長落後的那個區塊。因此我們預期 2027 年核心結石業務會改善。

  • And as you know, you've heard for many quarters now, we've struggled a bit with the Axonics integration. We've done great with the Silk Road integration, with Nalu integration, but we struggled with Axonics based on significant commercial turnover. We've done a lot to hire a lot of new reps and clinical people in that area. It takes a bit of time for them to get seasoned in their territories, but we expect to see improvement in that in 2027.

    另外如你所知,你也聽了好幾季了,我們在 Axonics 的整合上遇到一些困難。我們在 Silk Road 的整合、以及 Nalu 的整合做得很好,但由於顯著的商業團隊流動,我們在 Axonics 上遇到挑戰。我們已經做了很多工作,在那個領域招募了許多新的業務代表與臨床人員。他們需要一些時間在各自的區域成熟起來,但我們預期 2027 年會看到改善。

  • So in short, '27, we think Endo-Uro will be in that kind of lower to mid-single-digit range and Neuro slightly higher. And Endo and Uro both lapping significant China VBP pricing in fourth quarter '27 to have a stronger '28. But we -- overall, we do aim to get back to kind of that seven to eight-ish numbers that we used to see.

    簡而言之,2027 年我們認為 Endo 與 Uro 會落在偏低到中個位數的區間,而 Neuro 會略高一些。而 Endo 與 Uro 都會在 2027 年第四季跨過(lapping)中國 VBP 集採定價的顯著影響,從而在 2028 年更強勁。但整體而言,我們的目標確實是回到過去那種大約 7% 到 8% 左右的數字。

  • Operator

    Operator

  • Travis Steed, Bank of America.

    Travis Steed,美國銀行。

  • Travis Steed - Analyst

    Travis Steed - Analyst

  • I wanted to ask on the pipeline. There was a lot of things kind of across the board pushed out. Is there something bigger picture going on the pipeline of the derisking of the pipeline? And also, Jon, you mentioned better forecasting abilities. So just curious if you could elaborate on that as well?

    我想問一下產品管線。有很多事情看起來在各方面都被往後推遲了。產品管線是否有更宏觀的因素在發生,例如在對管線進行去風險(derisking)?另外,Jon,你提到更好的預測能力。所以也想請你就這點多做一些說明。

  • Jonathan Monson - Chief Financial Officer, Executive Vice President

    Jonathan Monson - Chief Financial Officer, Executive Vice President

  • Yes, Travis, I'll start on the forecasting question and then turn to Mike and Joe's in the room here to go through the pipeline. 2026 has been a challenging year for us, as Mike said, after several years of exceptional growth. driven in large part by EP and WATCHMAN, we've seen that cycle turn. So we're in a tough business cycle now because of the dynamics predominantly within those two businesses. And we've struggled to forecast that this year, and we need to be better. I recognize that, Mike knows that, Joe knows that. The whole team here knows that.

    好的,Travis,我先回答預測的問題,然後再請在場的 Mike 和 Joe 來談產品管線。如 Mike 所說,2026 年對我們而言是充滿挑戰的一年,因為在經歷了數年卓越成長之後。在很大程度上由 EP 與 WATCHMAN 所帶動,我們看到那個週期已經轉向。因此,由於主要集中在這兩項業務的動態,我們目前處於一個艱難的景氣循環中。而我們今年在預測上做得不夠好,我們需要做得更好。我認知到這點,Mike 知道這點,Joe 也知道這點。在座整個團隊都知道這點。

  • We feel we've got a clear picture of the business dynamics now. We've laid that out. We're taking action with the restructuring program. We have our new operating model, which will drive greater focus, greater speed, greater accountability. And from a forecasting process perspective, we've made a number of enhancements implemented more sensitivity and scenario analysis, more objective models, more third-party data that we pull in.

    我們覺得現在已經對業務動態有清晰的掌握。我們也已經把這些說明出來。我們正透過重整計畫採取行動。我們有新的營運模式,將帶來更高的聚焦、更快的速度、更強的問責。而在預測流程的角度,我們也做了多項強化:導入更多敏感度與情境分析、更客觀的模型,以及我們納入更多第三方數據。

  • So we feel if all of that together, you'll see improved forecasting actually from us on a go-forward basis. And with the guidance that we put forth for the fourth quarter here and the framework for 2027, very, very focused on delivering on that.

    因此我們認為,這些措施加總起來,你們將會看到我們在未來的預測能力確實有所改善。而對於我們提出的第四季指引以及 2027 年的框架,我們也會非常、非常專注於達成。

  • Mike, Joe, pipeline?

    Mike、Joe,產品管線呢?

  • Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

    Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

  • Maybe just quick things. We pride ourselves in executing. '26 has not been the year we've executed so well. So we're -- we've done a lot to tighten our performance. Jon just went through some of our forecasting areas. In terms of overall business, the business has gotten larger. So one of the reasons for the -- for Joe now becoming COO and breaking of the sector is to have even more focus on these sectors. So we improve our efficiency and reliability in terms of the dates that we give you for these big launches.

    也許我先簡短說幾點。我們一向以執行力為傲。但 2026 年並不是我們執行得很好的年份。因此我們做了很多工作來收緊、提升我們的績效表現。Jon 剛才也談到我們在預測方面的一些改善。就整體業務而言,公司的規模變得更大了。因此,讓 Joe 現在擔任 COO 並將事業部拆分,其中一個原因就是要對這些事業部有更高的聚焦。如此一來,我們能提升效率與可靠性,特別是在我們對外提供這些重大產品上市時程日期的準確性上。

  • We do have a very impressive pipeline that's coming for the company. We're down for a bit, but we're far from out and these pipeline products will come through and return Boston Scientific to its high-performance reputation that we want to earn back with you.

    我們確實為公司準備了一條非常令人印象深刻的產品管線。我們目前確實有些下滑,但遠未出局;這些管線產品將會推進落地,並讓波士頓科學重回我們希望與各位一同重新贏回的高績效聲譽。

  • Some of these products are complicated with clinical trials and regulatory processes. So we've kind of seen about a six month delay in some of these big platforms. We want to make sure we launch them at that high scale with high-quality and we aim to do that, but the pipeline is very rich, and we can go through some of those elements and Joe can provide more detail. But we're not happy with some of the flips. We've put a lot of focus on it, and we know the impact it has on the business.

    其中一些產品因臨床試驗與法規流程而相當複雜。因此我們在部分大型平台上大概看到約六個月的延遲。我們希望確保以高規模、高品質推出並以此為目標,但管線非常豐富;我們可以逐一說明其中一些要素,Joe 也能提供更多細節。但我們對某些反覆變動並不滿意。我們已投入大量心力聚焦改善,也了解這對業務的影響。

  • Operator

    Operator

  • Josh Jennings, TD Cowen.

    Josh Jennings,TD Cowen。

  • Joshua Jennings - Analyst

    Joshua Jennings - Analyst

  • Mike, I was hoping to just clarify just the outlook for the WAMGR as you've given strong good high color -- high-level color on '27 and '28. 2026 WAMGR is 7% is you got some pipeline products potentially could expand. But is the assumption baked into some of your high-level color in the out years that WAMGR is sustainable at that 7% level? And then just a side question, maybe just hoping to get an updated outlook on your view of the market, the US EP market and growth there as we move into '27 and '28?

    Mike,我想釐清一下你對 WAMGR 的展望;你已就 2027 與 2028 提供了相當強、很有資訊量的高層次說明。2026 年 WAMGR 是 7%,若有一些管線產品,可能還能擴張。但你在更遠期的高層次說明中,是否已假設 WAMGR 能在 7% 這個水準上具可持續性?另外一個附帶問題:也想請你更新一下你對市場的看法,特別是美國 EP 市場,以及我們邁向 2027、2028 時的成長情況?

  • Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

    Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

  • Yes. On the WAMGR, we don't -- we're not used to growing below our WAMGR. We think it's still about 7%. We've seen some pressure overall and maybe the Uro market and Endo markets that have pushed it down a bit to that 7% level. EP market continues to remain very strong. Obviously, the WATCHMAN market has pulled that WAMGR to that 7% range, but the WATCHMAN market is about a $2 billion market overall.

    是的。關於 WAMGR,我們不——我們不習慣成長低於我們的 WAMGR。我們認為仍大約是 7%。我們看到整體有些壓力,可能是泌尿(Uro)與內視鏡(Endo)市場把它稍微壓到約 7% 的水準。EP 市場仍然非常強勁。很明顯,WATCHMAN 市場把 WAMGR 拉到約 7% 的區間,但 WATCHMAN 市場整體約是 20 億美元的市場。

  • Importantly, as you look at the LRP, we're entering markets that grow faster than our WAMGR. The IVL market, potentially the hypertension market and some big launches in EP and segments that we don't play in today with ICE and also with FARAFLEX.

    重要的是,從 LRP 來看,我們正在進入成長速度快於我們 WAMGR 的市場:IVL 市場、潛在的高血壓市場,以及 EP 的一些重大上市案;還有我們目前尚未涉足的細分領域,例如 ICE,以及 FARAFLEX。

  • So I think overall, kind of that 7% WAMGR today in that 7% to maybe -- and then you're adding Penumbra, which is at scale, a accretive WAMGR to the business or at least in line. So I think that kind of 7% range now and maybe 7% to 8% over the next three years is about the right way to call it. When we look at '27 based on the comments that we made -- I'm sorry, when we look at '27, obviously growing below the WAMGR based on the comments that we made. And in '28, we aim to get back to closer to those WAMGR numbers and beyond.

    所以我認為整體而言,目前約 7% 的 WAMGR——而且你還加入了已具規模的 Penumbra,對業務的 WAMGR 是增益的,或至少是持平一致的。因此我認為現在大概在 7% 左右,未來三年可能在 7% 到 8% 的區間,是比較合理的說法。當我們看 2027 年,基於我們先前的評論——抱歉,當我們看 2027 年,顯然會低於 WAMGR 成長,這是基於我們所做的評論。而在 2028 年,我們的目標是回到更接近那些 WAMGR 的數字,甚至更高。

  • Operator

    Operator

  • Marie Thibault, US Bank BTIG.

    Marie Thibault,美國銀行 BTIG。

  • Marie Thibault - Analyst

    Marie Thibault - Analyst

  • I wanted to circle back to the commentary on no growth for 2027 when it comes to EPS. We heard Jon talk about some of the restructuring efforts that are being put in place. I know this quarter, you were able to offset things like expedited shipping costs related to the cyber-attack, you were able to offset some of that with a better OpEx control.

    我想回到你們對 2027 年 EPS 不成長的評論。我們聽到 Jon 談到一些正在推動的重整措施。我知道本季你們能夠抵銷例如與網路攻擊相關的加急運輸成本,你們也能透過更好的 OpEx 控制來抵銷其中一部分。

  • So think about all of this, when we think about no growth in adjusted EPS next year, is it really about product mix and some of those less profitable products being the contributors to sales growth? Or why else shouldn't we expect some adjusted EPS growth given some of the efforts you're putting in place?

    因此綜合來看,當我們思考明年調整後 EPS 不成長時,這真的是因為產品組合,以及一些獲利較低的產品成為銷售成長的主要貢獻者嗎?或者,除了這些之外,為什麼在你們推動這些措施的情況下,我們仍不應期待調整後 EPS 有所成長?

  • Jonathan Monson - Chief Financial Officer, Executive Vice President

    Jonathan Monson - Chief Financial Officer, Executive Vice President

  • Mix is the biggest factor, Marie. So as we talked about, do you see pressure on the top line, that pressure predominantly is with WATCHMAN and EP. So we'll feel the mix impact of that within gross margin. And then with the China pricing pressure that we see escalating, that will also impact gross margin in 2027 as well. And we do have some investment that we continue to make across supply chain, our quality systems.

    Marie,產品組合是最大的因素。如同我們談到的,你看到營收端的壓力,而這個壓力主要來自 WATCHMAN 與 EP。因此我們會在毛利率中感受到由此帶來的組合影響。另外,我們看到中國的定價壓力正在升高,這也會在 2027 年影響毛利率。而且我們仍持續在供應鏈、品質系統等方面進行投資。

  • So as you look ahead to 2027, and we'll give the guide in all the detail on the Q4 earnings call, but expect significant pressure in gross margin next year. And we'll continue to invest in the portfolio. We have a lot that we're excited about in the portfolio and want to make sure we're fully funding those initiatives.

    因此展望 2027 年——我們會在第四季財報電話會議中提供完整細節的指引——但可以預期明年毛利率將面臨顯著壓力。我們也會持續投資於產品組合。我們的產品組合中有很多令人振奮的項目,我們希望確保這些計畫都能獲得充分資金支持。

  • Now again, we will have restructuring that will help to offset some of those costs. We'll continue to be very disciplined with spend in 2027. But as you put that all together, I'd expect our EPS next year to be roughly in line with revenue and again, on our commentary, expect to be challenged to grow next year.

    另外,我們確實會有重整措施,有助於抵銷部分成本。2027 年我們也會持續在支出上保持高度紀律。但把這些因素合在一起,我預期明年我們的 EPS 大致會與營收表現一致;同樣依照我們的評論,明年要實現成長將會具有挑戰。

  • Operator

    Operator

  • Pito Chickering, Deutsche Bank.

    Pito Chickering,德意志銀行。

  • Pito Chickering - Research Analyst

    Pito Chickering - Research Analyst

  • Can you talk about what's causing the delay of the THRIVE data and therefore, the TIVUS launch and on VITALYST, I think you said you weren't looking at high-risk PCI. Can you talk about what you're seeing with the product? And do you think the market is still attractive with just shock?

    你能談談造成 THRIVE 數據延遲、因此也導致 TIVUS 上市延後的原因嗎?另外關於 VITALYST,我記得你說你們不會看高風險 PCI。你能談談你們在產品上看到的情況嗎?以及如果只聚焦於休克(shock),你認為這個市場仍然具有吸引力嗎?

  • Ken Stein - Chief Medical Officer

    Ken Stein - Chief Medical Officer

  • Yes, Pito, it's Ken. Maybe let me start with VITALYST. So there was data from a competitor released last year that I think called into question the broad use of mechanical circulatory support for high-risk PCI. We still believe that there is a role for that therapy there. But we do, I think, as field, need to figure out a better patient selection. The pivot to first studying cardiogenic shock it's very important to realize just how much of an unmet medical need there is in AMI cardiogenic shock. There is still mortality approaching 50% patients who present with acute MI on shock, and it occurs in up to 10% of patients who are having an ST elevation in MI.

    好的,Pito,我是 Ken。也許我先從 VITALYST 談起。去年競品公布了一些數據,我認為這讓機械循環支持在高風險 PCI 的廣泛使用受到質疑。我們仍相信該療法在那裡有其角色。但我認為我們整個領域需要找出更好的病人選擇方式。轉而先研究心因性休克(cardiogenic shock),非常重要的一點是要認知到 AMI 心因性休克仍存在多大的未被滿足醫療需求。急性心肌梗塞合併休克的病人死亡率仍接近 50%,而且在發生 ST 段抬高型心肌梗塞的病人中,最多可達 10% 會出現此情況。

  • Data was presented a couple of years ago. The DanGer Shock trial showed beyond a doubt that mechanical circulatory support can reduce mortality in those patients. So this is both an area of major need and an area where we know that mechanical circulatory support can improve outcomes. And we believe that with our VITALYST platform, we have differentiated advantages over the current incumbent in terms of dealing with shock.

    幾年前曾發表過數據。DanGer Shock 試驗毫無疑問地顯示,機械循環支持可以降低這些病人的死亡率。因此這既是重大未滿足需求的領域,也是我們已知機械循環支持能改善預後的領域。我們相信,憑藉 VITALYST 平台,相較於目前的既有領導者(incumbent),在處理休克方面我們具備差異化優勢。

  • VITALYST has a novel catheter design that improves positional stability, that's particularly important in dealing with shock patients, where the catheter needs to stay in place in the CCU for a longer period of time, along with strategies aimed at just minimizing the complexity of managing these patients and minimizing vascular complications. And so that's why we're so excited about the potential for the VITALYST platform and will actually we like the move into AMI shock as the first trial.

    VITALYST 具有新穎的導管設計,可提升位置穩定性;這在處理休克病人時特別重要,因為導管需要在 CCU 中維持更長時間的置放,同時也搭配策略以盡量降低管理這些病人的複雜度並減少血管併發症。因此我們對 VITALYST 平台的潛力感到非常興奮,而且我們其實也很喜歡把 AMI 休克作為第一個試驗的方向。

  • Lauren Tengler - Vice President, Investor Relations

    Lauren Tengler - Vice President, Investor Relations

  • And then on THRIVE?

    那 THRIVE 呢?

  • Ken Stein - Chief Medical Officer

    Ken Stein - Chief Medical Officer

  • On THRIVE, really, again, it's just a matter of continuing to execute on enrollment in the clinical trial. Enrollment, I think, frankly, has been a little bit slower than we would have hoped as we navigated the transition and the integration of the SoniVie team into the Boston Scientific ecosystem. But again, are confident that we can get that on track and that we will eventually finish enrollment of the trial.

    關於 THRIVE,基本上同樣是持續推進臨床試驗收案(enrollment)的執行問題。坦白說,在我們推動 SoniVie 團隊轉換並整合進波士頓科學體系的過程中,收案速度比我們原先希望的稍微慢了一些。但我們仍有信心能把進度拉回正軌,並最終完成該試驗的收案。

  • I believe in the technology. We do believe that ultrasound is the best of the energy sources that we can use for doing renal denervation. And we continue to believe that the THRIVE platform has differentiated advantages over the two current approved devices for renal denervation for hypertension.

    我相信這項技術。我們確實相信,超音波是我們可用於進行腎去神經術的最佳能量來源。而且我們持續相信,THRIVE 平台相較於目前兩款已獲核准、用於治療高血壓的腎去神經裝置,具備差異化優勢。

  • Operator

    Operator

  • Matthew O'Brien, Piper Sandler.

    Matthew O'Brien,Piper Sandler。

  • Matthew O'Brien - Analyst

    Matthew O'Brien - Analyst

  • Just a follow up on the pushback on the pipeline because that's what we're all kind of banking on at this point. Is the pipeline coming through? You just mentioned TIVUS and what's happening there. But with Ultra and with Flex, is it product related? Is it enrollment? Is it manufacturing? What's slowing things down in terms of getting those to market? And then just anything more you can provide on Penumbra and a modest push on the timing there? Is it more regulatory questions, specific product-related questions, just anything on those things.

    我想就產品線(pipeline)遭遇的阻力再追問一下,因為目前大家某種程度上都把希望寄託在這上面。產品線進展順利嗎?你剛提到 TIVUS 以及那邊的情況。但就 Ultra 和 Flex 而言,是產品本身的問題嗎?是受試者入組(enrollment)嗎?是製造嗎?到底是什麼在拖慢它們上市的進度?另外,關於 Penumbra 以及時程上小幅延後的原因,你還能提供更多資訊嗎?是更多監管方面的問題、特定的產品相關問題,或是其他任何相關資訊?

  • Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

    Michael Mahoney - Chairman of the Board, President, Chief Executive Officer

  • Yes, we won't provide any more updates on Penumbra other than what I commented on. We're very bullish on the transaction, and we're aiming to close that as early as we can. Likely, it will be pushing into early '27. In terms of the -- some of the product delays, Joe's here, Joe, you have any additional comments?

    是的,關於 Penumbra,我們不會提供超出我剛才評論之外的更多更新。我們對這筆交易非常看好,並且希望能盡早完成交割。很可能會延到 2027 年初。至於——一些產品延遲的部分,Joe 也在這裡,Joe,你有沒有補充?

  • Joseph Fitzgerald - Executive Vice President, Group President - Cardiovascular

    Joseph Fitzgerald - Executive Vice President, Group President - Cardiovascular

  • I'll take Ultra first. As you know, Ultra is a PMA supplement, does not require a clinical study. So most of the issues we have there are just on getting through what we call design verification and validation. And if you look at Ultra, that's a hardware, software and a catheter project. So the, let's call it, one quarter delay that you see is just a summary of issues that we have to work through with DV has nothing to do with anything on the clinical trial because we don't need clinical data to get Ultra approved.

    我先談 Ultra。如你所知,Ultra 是 PMA 補充申請(PMA supplement),不需要臨床研究。所以我們那邊的大部分問題,主要是在完成我們所稱的設計驗證與確認(design verification and validation)。如果你看 Ultra,它是一個硬體、軟體以及導管(catheter)的專案。因此,你看到的大約一季的延遲,只是我們在 DV 過程中需要解決的一些問題的總結,與任何臨床試驗無關,因為 Ultra 取得核准不需要臨床數據。

  • On FARAFLEX, I would call it three things. It is related to our negotiations with FDA on getting the actual IDE approved. We've had slight delays with CMS full approval. And there are some operational challenges getting everything that's needed to complete a FARAFLEX case done to expand the number of sites.

    至於 FARAFLEX,我會說有三個因素。第一,與我們和 FDA 就實際 IDE 核准所進行的協商有關。第二,我們在 CMS 完全核准(full approval)方面有些輕微延遲。第三,在營運面上,要把完成一例 FARAFLEX 手術所需的一切準備到位、並擴增站點數量,存在一些挑戰。

  • So we believe we will have that largely. We just got CMS, and we believe our supply chain to support the study will be pretty robust by end of year. So I think when we get on the Q4 call, a good question for us will be how is enrollment going in the FARAFLEX study, which we expect that to ramp each successive week and month going forward.

    所以我們相信這些大致上都能處理好。我們剛拿到 CMS(核准),並且我們相信到年底前,用以支援該研究的供應鏈會相當穩健。因此我認為等到第四季電話會議時,一個很好的問題會是:FARAFLEX 研究的入組進度如何?我們預期未來每一週、每一個月都會逐步加速。

  • Operator

    Operator

  • Matt Taylor, Jefferies.

    Matt Taylor,Jefferies。

  • Matthew Taylor - Equity Analyst

    Matthew Taylor - Equity Analyst

  • I wanted to follow up on the Penumbra, not on the timing. But could you talk about the kind of growth that you expect from that platform? And before you had said in the first year, it could be $0.06 to $0.08 dilutive, but some of the math there has changed. I was wondering if you could update us on that -- it's decelerated a little bit in the last couple of quarters. So I just want to get an update.

    我想追問一下 Penumbra,但不是關於時程。你能談談你們預期該平台的成長幅度嗎?另外你之前提到第一年可能會有每股盈餘(EPS)$0.06 到 $0.08 的稀釋,但其中一些計算基礎已經改變。我想請你更新一下——過去幾季它的成長似乎稍微放緩。所以我想了解最新狀況。

  • Jonathan Monson - Chief Financial Officer, Executive Vice President

    Jonathan Monson - Chief Financial Officer, Executive Vice President

  • Yes. Thanks, Matt. I'll take the dilution piece and then Mike and Joe can give quick comments on the growth profile. But we're excited to add Penumbra. You can see from their results, they're performing very well, high growth, would be a great addition to our cardiovascular portfolio.

    好的。謝謝,Matt。我先回答稀釋的部分,接著 Mike 和 Joe 可以簡短評論成長輪廓。不過我們很期待納入 Penumbra。從他們的業績表現你也看得到,他們表現非常好、成長率高,會是我們心血管產品組合很棒的補強。

  • So we announced Penumbra in mid-January, anticipate closing in early 2027 at this point. At the time of announcement, we had said we expected $0.06 to $0.08 of dilution and that assumes no divestitures that assumes interest rates that were in place at that time. We have seen increases in interest rates since then, so that will drive incremental financing costs. And I think we'll put additional pressure on the EPS dilution that we'd expect. But once we close the deal, we'll provide much more detail.

    我們在 1 月中旬宣布 Penumbra,目前預期在 2027 年初完成交割。在宣布當時,我們說過預期會有每股 $0.06 到 $0.08 的稀釋,且那是假設不進行任何資產剝離(divestitures),並假設利率維持在當時的水準。此後我們看到利率上升,這將帶來額外的融資成本。我認為這會對我們預期的 EPS 稀釋造成進一步壓力。但一旦交易完成,我們會提供更詳細的資訊。

  • Lauren Tengler - Vice President, Investor Relations

    Lauren Tengler - Vice President, Investor Relations

  • Thanks so much, Jon. Thank you for joining us today. We appreciate your interest in Boston Scientific. If we were unable to get to your question or if you have any follow-ups, please don't hesitate to reach out to the Investor Relations team.

    非常感謝你,Jon。也謝謝你今天加入我們。我們感謝你對波士頓科學(Boston Scientific)的關注。如果我們未能回答到你的問題,或你有任何後續問題,請隨時聯繫投資人關係團隊。

  • Before you disconnect, Drew will give you all of the pertinent details for the replay. Thanks, everyone.

    在你斷線之前,Drew 會提供所有與重播相關的重要細節。謝謝各位。

  • Operator

    Operator

  • Thank you. (Operator Instructions) The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.

    謝謝。(接線員指示)本次電話會議到此結束。感謝各位參加今天的簡報。您現在可以斷線。